12 September 2016
US scientists have identified a protein that offers potential as a target for future cancer treatments.
A team from the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai examined a protein, known as kinase suppressor of Ras (KSR), a pseudoenzyme that plays a key role in transmitting signals in the cell to determine whether it will grow, divide or die.
Ras is the most frequently mutated human cancer gene, but to date there has been limited progress in the development of new therapies addressing this target. The lead compound used in this study, APS-2-79, was shown to modulate Ras signaling and increased the potency of several other cancer drugs.
Lead researcher Dr Arvin Dar, assistant professor of oncological sciences and sciences at the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai, said: "Our study opens the possibility of modulating KSR as a new cancer therapy and also potentially an entirely new class of interventions."
Previous studies had supported the potential of targeting oncogenic forms of Ras via KSR, this is the first time an effective pharmacological approach has been shown to be effective.
Posted by Philip Briggs
Health News is provided by Axonn Media in collaboration with Spire Healthcare. Please note that all copy above is ©Axonn Media and does not reflect views or opinions of Spire Healthcare unless explicitly stated. Additional comments on the page from individual Spire consultants do not necessarily reflect the views or opinions of other consultants or Spire Healthcare.